Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

Although the FDA has expanded approvals for two respiratory syncytial virus (RSV) vaccines to include high-risk young and ...

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

Analysts at Berenberg lowered their target price on drugmaker GSK from £18.20 to £16.00 on Monday after hosting chief ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Citi said that while it understands these concerns, BAE Systems has similar expected profit growth to US peers, better free ...

GSK has received approval from Japan's MHLW for its application to extend the indication of its RSV vaccine, Arexvy.

The EC has granted approval for presentation of GSK's Menveo vaccine (MenACWY) for invasive meningococcal disease (IMD).

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, ...

GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include ...

The latest health news includes the tragic death of two Australians from methanol poisoning in Laos, approval of GSK's RSV ...

(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider ...